Observational analyses of data from population registeries have suggested that metformin may
be associated with a decreased prevalence of malignancy. The ADOPT and RECORD studies both
contain groups of subjects randomly allocated to metformin and rosiglitazone. This
meta-analysis combines malignancy serious adverse events from ADOPT and RECORD in order to
compare their incidence on metformin with that on rosiglitazone.